Cognitive Impairment in Older Adults With Hematologic Malignancies

September 24, 2026 updated by: Khloud Khaled Fawzy Kotby, Assiut University

Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy

This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.

Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Kholoud K Fawzy, Resident
Phone Number: 01009850621
Email: khloud.18313604@med.aun.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.

Description

Inclusion Criteria:

- Age 65 years or older
Confirmed diagnosis of hematologic malignancy
Currently receiving chemotherapy
Able to communicate and participate in cognitive assessment
Written informed consent

Exclusion Criteria:

- Previously diagnosed dementia before the diagnosis of malignancy
Delirium at the time of assessment
Severe visual or hearing impairment interfering with cognitive testing
History of major neurological disorders affecting cognition
Severe psychiatric illness affecting cognitive assessment
Critically ill patients unable to complete study assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: CASE_ONLY
Time Perspectives: CROSS_SECTIONAL

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Single cohort: Older adults with hematologic malignancies Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of cognitive impairment Time Frame: Baseline	Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.	Baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean MoCA score Time Frame: Baseline	Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition)..	Baseline
Mean Katz ADL score Time Frame: Baseline	Mean Katz Index of Independence in Activities of Daily Living score (range 0-6, higher scores indicate greater independence).	Baseline
Mean Lawton IADL score Time Frame: Baseline	Mean Lawton Instrumental Activities of Daily Living score (range 0-8, higher scores indicate greater independence)	Baseline
Proportion with impaired activities of daily living Time Frame: Baseline	Proportion of participants with impaired Katz ADL score.	Baseline
Proportion with impaired instrumental activities of daily living Time Frame: Baseline	Proportion of participants with impaired Lawton IADL score.	Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

Study Chair: Soher M kasem, prof, Internal Medicine Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 26, 2026

Primary Completion (Estimated)

September 26, 2027

Study Completion (Estimated)

February 25, 2028

Study Registration Dates

First Submitted

September 21, 2026

First Submitted That Met QC Criteria